1-Cyclopentyl-4-isopropylpiperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-Cyclopentyl-4-isopropylpiperazine
• 英文别名: 1-cyclopentyl-4-propan-2-ylpiperazine
• 化学式: C₁₂H₂₄N₂
• 分子量: 196.33
• InChiKey: SGFFXDHXCZIMGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• JANUS KINASE INHIBITOR COMPOUNDS AND METHODS
  申请人：GOODACRE SIMON CHARLES

  公开号：US20100317643A1

  公开（公告）日：2010-12-16

  The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R 1 , R 2 , R 4 and R 5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof

  这项发明提供了公式I的化合物，其立体异构体或药学上可接受的盐，其中A、B、D、R1、R2、R4和R5在此处被定义，包括公式I化合物的药物组合物以及其使用方法
• PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS
  申请人：Mantoulidis Andreas

  公开号：US20120094975A1

  公开（公告）日：2012-04-19

  The present invention encompasses compounds of general formula (1) wherein the groups R 1 to R 4 , X 1 , X 1 , X 3 , L 1 and L 2 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or anomalous cell pro-liferation, and the use thereof in such a treatment.

  本发明涵盖了一般式（1）中的化合物，其中基团R1至R4、X1、X1、X3、L1和L2如权利要求1中定义的那样，适用于治疗以细胞过度或异常增殖为特征的疾病，并且在此类治疗中的使用。
• Sulfonamide-substituted chalcone derivatives and their use to treat diseases
  申请人：Worsencroft J. Kimberly

  公开号：US20070093453A1

  公开（公告）日：2007-04-26

  The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

  本发明涉及一般式化合物、药物组合物以及使用该化合物的方法，或其药学上可接受的盐或酯，其中取代基在申请中定义。
• PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES
  申请人：Ettmayer Peter

  公开号：US20120046270A1

  公开（公告）日：2012-02-23

  The present invention encompasses compounds of general formula (1), wherein the groups R 1 to R 4 , X 1 , X 2 , X 3 , X 4 , X 5 , Q, L 1 and L 2 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.

  本发明涵盖了通式（1）的化合物，其中R1到R4，X1，X2，X3，X4，X5，Q，L1和L2的基团如权利要求1中所定义，这些化合物适用于治疗由细胞过度增殖或异常增殖所特征的疾病，以及这些化合物的制药制剂和配方。
• B-RAF KINASE INHIBITORS
  申请人：Steurer Steffen

  公开号：US20130190286A1

  公开（公告）日：2013-07-25

  The present invention encompasses compounds of general formula (1) where in the groups R 0 to R 3 and L are defined as in claim 1 , which are suitable for the 5 treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

  本发明涵盖了通式（1）的化合物，其中R0到R3和L的定义如权利要求1所述，适用于治疗由过度或异常细胞增殖所特征的疾病，包含这种化合物的制药制剂以及它们作为药物的使用。